Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Investments: 2021-2022

  • ARS Pharmaceuticals' Long-Term Investments was N/A to $24.2 million in Q2 2022 from the same period last year, while for Jun 2022 it was $24.2 million, marking a year-over-year change of. This contributed to the annual value of $64.8 million for FY2021, which is N/A change from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Long-Term Investments of $24.2 million as of Q2 2022, which was down 44.93% from $44.0 million recorded in Q1 2022.
  • In the past 5 years, ARS Pharmaceuticals' Long-Term Investments ranged from a high of $64.8 million in Q4 2021 and a low of $24.2 million during Q2 2022.
  • Moreover, its 2-year median value for Long-Term Investments was $42.0 million (2021), whereas its average is $43.2 million.